CL2012000948A1 - Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. - Google Patents

Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.

Info

Publication number: CL2012000948A1
Authority: CL; Chile
Prior art keywords: idm; atanol; propinate; hfa; fluticasone
Prior art date: 2009-10-16

Application number

CL2012000948A

Other languages

English (en)

Inventor

Walz Rudi Fueg Lise Marie Mueller

Original Assignee

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-16

Filing date

2012-04-13

Publication date

2012-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000948(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-04-13 Application filed by Jagotec Ag filed Critical Jagotec Ag

2012-12-14 Publication of CL2012000948A1 publication Critical patent/CL2012000948A1/es

Links

RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 title 1
239000000443 aerosol Substances 0.000 title 1
208000006673 asthma Diseases 0.000 title 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title 1
229960002714 fluticasone Drugs 0.000 title 1
229960003610 formoterol fumarate dihydrate Drugs 0.000 title 1
238000009472 formulation Methods 0.000 title 1
229940071648 metered dose inhaler Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
PDEFQWNXOUGDJR-UHFFFAOYSA-M sodium;2,2-dichloropropanoate Chemical compound [Na+].CC(Cl)(Cl)C([O-])=O PDEFQWNXOUGDJR-UHFFFAOYSA-M 0.000 title 1
239000000725 suspension Substances 0.000 title 1
239000000080 wetting agent Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CL2012000948A 2009-10-16 2012-04-13 Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. CL2012000948A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0918150.4A GB0918150D0 (en)	2009-10-16	2009-10-16	Improved formulations

Publications (1)

Publication Number	Publication Date
CL2012000948A1 true CL2012000948A1 (es)	2012-12-14

Family

ID=41462451

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012000948A CL2012000948A1 (es)	2009-10-16	2012-04-13	Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.

Country Status (25)

Country	Link
US (2)	US20120263766A1 (es)
EP (2)	EP2488157B1 (es)
JP (2)	JP5818801B2 (es)
CN (1)	CN102573791B (es)
AU (1)	AU2010305695B2 (es)
BR (1)	BR112012008969B1 (es)
CA (1)	CA2776845C (es)
CL (1)	CL2012000948A1 (es)
CY (1)	CY1123918T1 (es)
DK (1)	DK2488157T3 (es)
ES (1)	ES2859629T3 (es)
GB (1)	GB0918150D0 (es)
HR (1)	HRP20210379T1 (es)
HU (1)	HUE054030T2 (es)
IL (2)	IL219162A0 (es)
LT (1)	LT2488157T (es)
MX (1)	MX372991B (es)
NZ (1)	NZ599900A (es)
PL (1)	PL2488157T3 (es)
PT (1)	PT2488157T (es)
RS (1)	RS61430B1 (es)
SI (1)	SI2488157T1 (es)
SM (1)	SMT202100150T1 (es)
WO (1)	WO2011045429A1 (es)
ZA (1)	ZA201202595B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1372608E (pt) *	2001-03-30	2008-01-04	Jagotec Ag	Formulações de aerossol médicas
GB0323684D0 (en)	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0918150D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved formulations
GB0918149D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved medicinal aerosol formulation
EP2819669B1 (de) *	2012-02-28	2021-04-21	Boehringer Ingelheim International GmbH	Neue treibgashaltige tiotropium-formulierung
KR20150002774A (ko)	2012-04-11	2015-01-07	시플라 리미티드	아르포르모테롤 및 플루티카손 푸로에이트를 포함하는 약학 조성물
GB201321712D0 (en) *	2013-12-09	2014-01-22	Pharmachemie Bv	Dry Powder Inhaler
CN105963282B (zh) *	2016-05-04	2019-04-19	四川普锐特医药科技有限责任公司	一种医用定量吸入气雾剂
CN109789107B (zh) *	2016-09-29	2021-12-03	广东东阳光药业有限公司	药物组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596260B1 (en)	1993-08-27	2003-07-22	Novartis Corporation	Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
MX9707864A (es)	1995-04-14	1997-11-29	Glaxo Wellcome Inc	Inhalador de dosis medida por salmeterol.
DE69637257T2 (de)	1995-04-14	2008-06-12	Smithkline Beecham Corp.	Verfahren zur Herstellung eines Dosierinhalators
JPH101442A (ja) *	1996-06-12	1998-01-06	Taisho Pharmaceut Co Ltd	鼻炎用点鼻薬
CZ295460B6 (cs) *	1997-03-20	2005-08-17	Schering Corporation	Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující
GB9903759D0 (en) *	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
AU5070100A (en) *	2000-05-22	2001-12-03	Chiesi Farma Spa	Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP1318952A2 (en)	2000-09-18	2003-06-18	Glaxo Group Limited	Coated can for a metered dose inhaler
CA2425035A1 (en) *	2000-10-09	2002-04-18	3M Innovative Properties Company	Medicinal aerosol formulations
PT1372608E (pt) *	2001-03-30	2008-01-04	Jagotec Ag	Formulações de aerossol médicas
US6667344B2 (en) *	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
GB0201400D0 (en) *	2002-01-22	2002-03-13	Glaxo Group Ltd	Novel apparatus and process
CA2496699C (en) *	2002-08-29	2012-07-17	Cipla Ltd.	Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
GB0323684D0 (en) *	2003-10-09	2003-11-12	Jagotec Ag	Improvements in or relating to organic compounds
GB0327727D0 (en) *	2003-11-28	2003-12-31	Quadrant Drug Delivery Ltd	Viral microparticles
GB0410399D0 (en) *	2004-05-10	2004-06-16	Arakis Ltd	The treatment of respiratory disease
GB0918150D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved formulations

2009
- 2009-10-16 GB GBGB0918150.4A patent/GB0918150D0/en not_active Ceased
2010
- 2010-10-15 DK DK10768760.0T patent/DK2488157T3/da active
- 2010-10-15 HU HUE10768760A patent/HUE054030T2/hu unknown
- 2010-10-15 AU AU2010305695A patent/AU2010305695B2/en active Active
- 2010-10-15 US US13/502,097 patent/US20120263766A1/en not_active Abandoned
- 2010-10-15 JP JP2012533648A patent/JP5818801B2/ja active Active
- 2010-10-15 SI SI201032050T patent/SI2488157T1/sl unknown
- 2010-10-15 RS RS20210159A patent/RS61430B1/sr unknown
- 2010-10-15 MX MX2012004338A patent/MX372991B/es active IP Right Grant
- 2010-10-15 LT LTEP10768760.0T patent/LT2488157T/lt unknown
- 2010-10-15 WO PCT/EP2010/065569 patent/WO2011045429A1/en not_active Ceased
- 2010-10-15 ES ES10768760T patent/ES2859629T3/es active Active
- 2010-10-15 CA CA2776845A patent/CA2776845C/en active Active
- 2010-10-15 HR HRP20210379TT patent/HRP20210379T1/hr unknown
- 2010-10-15 PT PT107687600T patent/PT2488157T/pt unknown
- 2010-10-15 BR BR112012008969-2A patent/BR112012008969B1/pt active IP Right Grant
- 2010-10-15 EP EP10768760.0A patent/EP2488157B1/en active Active
- 2010-10-15 EP EP20213235.3A patent/EP3811928A1/en not_active Withdrawn
- 2010-10-15 SM SM20210150T patent/SMT202100150T1/it unknown
- 2010-10-15 PL PL10768760T patent/PL2488157T3/pl unknown
- 2010-10-15 NZ NZ599900A patent/NZ599900A/en unknown
- 2010-10-15 CN CN201080046305.6A patent/CN102573791B/zh active Active
2012
- 2012-04-11 ZA ZA2012/02595A patent/ZA201202595B/en unknown
- 2012-04-13 CL CL2012000948A patent/CL2012000948A1/es unknown
- 2012-04-15 IL IL219162A patent/IL219162A0/en unknown
2015
- 2015-09-29 JP JP2015191177A patent/JP2016040286A/ja active Pending
2017
- 2017-03-21 US US15/464,879 patent/US20180296468A2/en not_active Abandoned
2019
- 2019-09-15 IL IL26936919A patent/IL269369A/en unknown
2021
- 2021-03-05 CY CY20211100190T patent/CY1123918T1/el unknown

Also Published As

Publication number	Publication date
IL219162A0 (en)	2012-06-28
JP5818801B2 (ja)	2015-11-18
NZ599900A (en)	2014-11-28
GB0918150D0 (en)	2009-12-02
JP2016040286A (ja)	2016-03-24
EP2488157B1 (en)	2020-12-30
MX2012004338A (es)	2012-08-01
JP2013507429A (ja)	2013-03-04
ZA201202595B (en)	2023-07-26
IL269369A (en)	2019-11-28
DK2488157T3 (da)	2021-01-25
EP2488157A1 (en)	2012-08-22
US20120263766A1 (en)	2012-10-18
AU2010305695B2 (en)	2014-07-10
SI2488157T1 (sl)	2021-02-26
HUE054030T2 (hu)	2021-08-30
US20180296468A2 (en)	2018-10-18
CA2776845C (en)	2018-04-24
US20170281529A1 (en)	2017-10-05
RS61430B1 (sr)	2021-03-31
BR112012008969B1 (pt)	2021-07-06
PT2488157T (pt)	2021-02-05
CN102573791B (zh)	2017-09-22
HRP20210379T1 (hr)	2021-04-16
PL2488157T3 (pl)	2021-06-28
ES2859629T3 (es)	2021-10-04
MX372991B (es)	2020-06-18
WO2011045429A1 (en)	2011-04-21
CN102573791A (zh)	2012-07-11
LT2488157T (lt)	2021-02-10
AU2010305695A1 (en)	2012-05-03
CY1123918T1 (el)	2022-05-27
CA2776845A1 (en)	2011-04-21
SMT202100150T1 (it)	2021-05-07
EP3811928A1 (en)	2021-04-28
BR112012008969A2 (pt)	2020-06-23

Publication	Publication Date	Title
CL2012000948A1 (es)	2012-12-14	Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.
EA201590179A1 (ru)	2015-09-30	Комбинированная терапия copd
MX393243B (es)	2025-03-24	Composición farmacéutica que comprende la combinación de albuterol y budesónida, adaptada para el suministro respiratorio mediante un inhalador de dosis medida y el uso de las mismas para el tratamiento de trastornos pulmonares.
PE20140101A1 (es)	2014-02-06	Formulacion para inhalacion que comprende aclidinio
UY31235A1 (es)	2009-03-02	Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
JP2007106777A5 (es)	2007-12-27
CO2022012449A2 (es)	2022-09-09	Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
ATE541603T1 (de)	2012-02-15	Inhalator für pulverförmige substanzen
JP2010132695A5 (es)	2011-12-08
PE20160155A1 (es)	2016-04-01	Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos
JP2014530231A5 (es)	2014-12-25
GB201118188D0 (en)	2011-12-07	Manufacture of medicinal aerosol canisters
UY34838A (es)	2014-03-31	Nueva forma de dosificación y formulación
MX2015007912A (es)	2016-03-03	Inhalador de polvo seco y metodo de uso.
MX2014004364A (es)	2014-05-27	Composiciones que comprenden sulfato de salbutamol.
IL201632A (en)	2016-09-29	Use of Formoterol and Clomethazone Dipropionate-containing Preparations for the Preparation of Medication for Use in Acute Acute Episodes
DK2089008T3 (da)	2011-10-24	Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator
TR201000622A2 (tr)	2011-08-22	Tiotropyum içeren farmasötik kombinasyonlar.
HRP20160630T1 (hr)	2016-07-01	Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata
CL2012000947A1 (es)	2012-12-14	Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
CO2022007719A2 (es)	2022-06-10	Lata de acero inoxidable para inhaladores dosificadores presurizados
TR200909788A2 (tr)	2011-07-21	Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
Newhouse et al.	2014	D34 AEROSOLIZED MEDICATIONS: SPECIFICATIONS AND TREATMENT CONSIDERATIONS: In Vitro Comparison Of Aerosol Characteristics Of Two Hfa Pmdi Formulations Used In Asthma And COPD With Inspirachamber® And Aerochamber Plus Flow-Vu®
AR085443A1 (es)	2013-10-02	Formulaciones medicinales en aerosol que no dañan la capa de ozono y con bajo efecto invernadero
PH12014500440A1 (en)	2014-04-28	Method for preparing metered dose sprayed inhaler for treating respiratory disease